Oct 31 (Reuters) - Mallinckrodt (NYSE:MNK) Plc MNK.N :
* MALLINCKRODT ANNOUNCES UVADEX® (METHOXSALEN) APPROVED IN AUSTRALIA FOR USE WITH THE THERAKOS® CELLEX® PHOTOPHERESIS SYSTEM FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AND SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA (CTCL) IN ADULTS
* MALLINCKRODT PLC - UVADEX HAS RECEIVED REGULATORY APPROVAL IN AUSTRALIA FOR EXTRACORPOREAL ADMINISTRATION WITH THERAKOS PHOTOPHERESIS SYSTEM